The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
=== EC 1.12.98 With other known acceptors === EC 1.12.98.1: coenzyme F420 hydrogenase EC 1.12.98.2: 5,10-methenyltetrahydromethanopterin hydrogenase EC 1.12.98.3: Methanosarcina-phenazine hydrogenase EC 1.12.98.4: Sulfhydrogenase
Tylosin is a macrolide antibiotic and bacteriostatic feed additive used in veterinary medicine. It has a broad spectrum of activity against Gram-positive organisms and a limited range of Gram-negative organisms. It is found naturally as a fermentation product of Streptomyces fradiae. Tylosin is used in veterinary medicine to treat bacterial infections in a wide range of species and has a high margin of safety. It has also been used as a growth promotant in some species, and as a treatment for colitis in companion animals.
== Mechanism of action == The mechanism of action is not fully understood, but nitrofurazone's antimicrobial properties are suspected to be due to the interference of DNA synthesis in the microorganism by inhibiting certain enzymes that are involved with glycolysis. Other enzymes this may affect include, pyruvate dehydrogenase, citrate synthetase, malate dehydrogenase, glutathione reductase, and pyruvate decarboxylase.
Sources: en.wikipedia.org
Another submarine, USS Cavalla, was able to maneuver to an attack position on the 25,675-ton carrier Shōkaku by about noon. The submarine fired a spread of six torpedoes, three of which struck Shōkaku on her starboard side. Badly damaged, the carrier came to a halt. One torpedo had hit the forward aviation fuel tanks near the main hangar, and aircraft that had just landed and were being refueled exploded into flames. Ammunition and exploding bombs added to the conflagration, as did burning fuel spewing from shattered fuel pipes. With her bows subsiding into the sea and fires out of control, the captain gave orders to abandon ship. Within minutes, there was a catastrophic explosion of aviation fuel vapor which had built up between decks, which blew the ship apart. The carrier rolled over and sank about 140 miles (230 km) north of the island of Yap. 887 crew and 376 men of the 601st Naval Air Group, 1,263 men in all, were killed. There were 570 survivors, including the carrier's commanding officer, Captain Hiroshi Matsubara. Destroyer Urakaze attacked the submarine, but Cavalla escaped with relatively minor damage despite near misses from depth charges. Meanwhile, Taihō was falling victim to poor damage control. Hoping to clear the explosive fumes, an inexperienced damage-control officer ordered her ventilation system to operate at full blast. This action instead spread the vapors throughout Taihō, putting the entire vessel at risk.
Rudolph Emile 'Rudy' Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, and director of the Genetics and Aging Research Unit and director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital (MGH). Dr. Rudy Tanzi has been investigating the genetics of neurological disease since the 1980s. He co-discovered all three familial early-onset Alzheimer's disease (FAD) genes and several other neurological disease genes including that responsible for Wilson’s disease. His team was the first to use human stem cells to create three-dimensional cell culture organoids of AD, dubbed “Alzheimer's-in-a-Dish”. The 3-D model made drug screening for AD faster and more cost-effective. He has published over 800 research papers and has received the Metropolitan Life Award and Potamkin Prize, the two highest awards for Alzheimer’s research. He is also a member of the National Academy of Medicine and was on the TIME100 Most Influential People in the World list in 2015.
Journal of Military History. 65 (3): 617–640. doi:10.2307/2677528. JSTOR 2677528. S2CID 159945703. McEvedy, Colin; Jones, Richard (1978). Atlas of World Population History. Facts on File. ISBN 978-0-87196-402-1. McLynn, Frank (1998). Napoleon: A Biography. Pimlico. ISBN 978-0-7126-6247-5. Munch-Petersen, Thomas (2007). Defying Napoleon: How Britain Bombarded Copenhagen and Seized the Danish Fleet in 1807. Sutton. ISBN 978-0-7509-4280-5. Palmer, Robert Roswell (1941). Twelve who Ruled: The Committee of Public Safety, During the Terror. Princeton University Press. Palmer, Alan (1974). Alexander I: Tsar of War and Peace. Weidenfeld & Nicolson. ISBN 978-0-297-76700-8. Palmer, R. R.; Colton, Joel; Kramer, Lloyd (2013). A History of the Modern World: 11th Edition. McGraw-Hill Higher Education. ISBN 978-0-07-759962-1. Payne, Stanley G. (1973). A History of Spain and Portugal: Eighteenth Century to Franco. Vol. 2. Madison: University of Wisconsin Press. ISBN 978-0299062705. Retrieved 2 May 2021. Philo, Tom (2010), Military and Civilian War Related Deaths Through the Ages, archived from the original on 20 April 2010 Rapport, Mike (2013). The Napoleonic Wars: A Very Short Introduction. OUP Oxford. ISBN 978-0-19-164251-7. Riehn, Richard K. (1990). 1812: Napoleon's Russian Campaign. McGraw-Hill. ISBN 978-0-07-052731-7. Riehn, Richard K. (1991), 1812: Napoleon's Russian Campaign (Paperback ed.), New York: Wiley, ISBN 978-0-471-54302-2 Riley, J. P. (2013). Napoleon and the World War of 1813: Lessons in Coalition Warfighting. Routledge. ISBN 978-1-136-32135-1. Roberts, Andrew (2014).
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.